130 related articles for article (PubMed ID: 38785475)
1. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study.
Moffat GT; Coyne Z; Albaba H; Aung KL; Dodd A; Espin-Garcia O; Moura S; Gallinger S; Kim J; Fraser A; Hutchinson S; Moulton CA; Wei A; McGilvray I; Dhani N; Jang R; Elimova E; Moore M; Prince R; Knox J
Curr Oncol; 2024 May; 31(5):2589-2597. PubMed ID: 38785475
[No Abstract] [Full Text] [Related]
2. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.
Mehtsun WT; McCleary NJ; Maduekwe UN; Wolpin BM; Schrag D; Wang J
JAMA Oncol; 2022 Jan; 8(1):88-95. PubMed ID: 34854874
[TBL] [Abstract][Full Text] [Related]
4. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Mohindroo C; Hasanov M; Rogers JE; Dong W; Prakash LR; Baydogan S; Mizrahi JD; Overman MJ; Varadhachary GR; Wolff RA; Javle MM; Fogelman DR; Lotze MT; Kim MP; Katz MHG; Pant S; Tzeng CD; McAllister F
Cancer Med; 2021 Aug; 10(15):5041-5050. PubMed ID: 34250759
[TBL] [Abstract][Full Text] [Related]
6. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Itchins M; Arena J; Nahm CB; Rabindran J; Kim S; Gibbs E; Bergamin S; Chua TC; Gill AJ; Maher R; Diakos C; Wong M; Mittal A; Hruby G; Kneebone A; Pavlakis N; Samra J; Clarke S
Eur J Surg Oncol; 2017 Sep; 43(9):1711-1717. PubMed ID: 28688722
[TBL] [Abstract][Full Text] [Related]
7. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
8. Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium.
Ethun CG; Lopez-Aguiar AG; Pawlik TM; Poultsides G; Idrees K; Fields RC; Weber SM; Cho C; Martin RC; Scoggins CR; Shen P; Schmidt C; Hatzaras I; Bentrem D; Ahmad S; Abbott D; Kim HJ; Merchant N; Staley CA; Kooby DA; Maithel SK
J Am Coll Surg; 2017 Apr; 224(4):406-413. PubMed ID: 28017812
[TBL] [Abstract][Full Text] [Related]
9. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
10. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
11. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
12. Incidental pulmonary embolism in pancreatic ductal adenocarcinoma: Impact of tumor and AJCC stages at initial staging CT.
Schawkat K; Tabah N; Tridente D; Schlechter BL; Singer T; Decicco C; Moser AJ; Mortele KJ
Pancreatology; 2019 Oct; 19(7):979-984. PubMed ID: 31522961
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
14. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
15. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma.
Shimomura O; Oda T; Hashimoto S; Doi M; Hiroshima Y; Numajiri H; Takahashi K; Furuya K; Miyazaki Y; Owada Y; Ogawa K; Ohara Y; Hisakura K; Akashi Y; Enomoto T; Sakurai H
Surg Oncol; 2021 Jun; 37():101542. PubMed ID: 33740629
[TBL] [Abstract][Full Text] [Related]
16. A pancreatic cancer multidisciplinary clinic: insights and outcomes.
Schiffman SC; Abberbock S; Winters S; Valko C; Steve J; Zureikat AH; Zeh HJ; Hogg ME
J Surg Res; 2016 May; 202(2):246-52. PubMed ID: 27229097
[TBL] [Abstract][Full Text] [Related]
17. Computerized tomography scan in pre-diagnostic pancreatic ductal adenocarcinoma: Stages of progression and potential benefits of early intervention: A retrospective study.
Singh DP; Sheedy S; Goenka AH; Wells M; Lee NJ; Barlow J; Sharma A; Kandlakunta H; Chandra S; Garg SK; Majumder S; Levy MJ; Takahashi N; Chari ST
Pancreatology; 2020 Oct; 20(7):1495-1501. PubMed ID: 32950386
[TBL] [Abstract][Full Text] [Related]
18. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
19. Age and prognosis in patients with pancreatic cancer: a population-based study.
van Dongen JC; van der Geest LGM; de Meijer VE; van Santvoort HC; de Vos-Geelen J; Besselink MG; Groot Koerkamp B; Wilmink JW; van Eijck CHJ;
Acta Oncol; 2022 Mar; 61(3):286-293. PubMed ID: 34935577
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment.
Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH
J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
